Detalhe da pesquisa
1.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 375(20): 1946-1960, 2016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959607
2.
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet
; 390(10090): 135-144, 2017 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28527704
3.
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
Am J Gastroenterol
; 113(11): 1678-1688, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30022113
4.
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Am J Gastroenterol
; 109(2): 212-23, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24394749
5.
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Am J Gastroenterol
; 107(9): 1409-22, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22890223
6.
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
Inflamm Bowel Dis
; 24(3): 490-501, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29462395
7.
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
Inflamm Bowel Dis
; 16(4): 620-9, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19714757
8.
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Clin Gastroenterol Hepatol
; 4(5): 621-30, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16678077
9.
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Am J Gastroenterol
; 101(5): 1030-8, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16606351
10.
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Am J Gastroenterol
; 97(10): 2577-84, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12385442